Apollomics announces the first approval of vebreltinib for met exon 14 skip non-small cell lung cancer

Apollomics' partner, avistone biotechnology, received approval from chinese national medical products administration (nmpa) to commercialize vebreltinib (apl-101) in china compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest of world foster city, calif., nov. 16, 2023 (globe newswire) -- apollomics inc. (nasdaq: aplm), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in china, avistone biotechnology co. ltd.
APLM Ratings Summary
APLM Quant Ranking